CLOVIS ONCOLOGY, INC.

(CLVS)
  Report
Delayed Nasdaq  -  04:00 2022-08-09 pm EDT
1.270 USD   -12.41%
08/08CLOVIS ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/08TRANSCRIPT : Clovis Oncology, Inc., Q2 2022 Earnings Call, Aug 08, 2022
CI
08/08CLOVIS ONCOLOGY : Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs - Form 8-K
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
1.65(c) 1.64(c) 1.66(c) 1.45(c) 1.27(c) Last
2 740 998 3 472 933 4 097 020 6 789 483 4 516 597 Volume
+3.13% -0.61% +1.22% -12.65% -12.41% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 130 M - -
Net income 2022 -229 M - -
Net Debt 2022 312 M - -
P/E ratio 2022 -0,74x
Yield 2022 -
Sales 2023 206 M - -
Net income 2023 -165 M - -
Net Debt 2023 326 M - -
P/E ratio 2023 -1,28x
Yield 2023 -
Capitalization 183 M 183 M -
EV / Sales 2022 3,80x
EV / Sales 2023 2,48x
Nbr of Employees 413
Free-Float 98,6%
More Financials
Company
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent... 
More about the company
Ratings of Clovis Oncology, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about CLOVIS ONCOLOGY, INC.
08/08CLOVIS ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
08/08TRANSCRIPT : Clovis Oncology, Inc., Q2 2022 Earnings Call, Aug 08, 2022
CI
08/08CLOVIS ONCOLOGY : Announces Second Quarter 2022 Operating Results and Provides Update on C..
PU
08/08CLOVIS : Q2 Earnings Snapshot
AQ
08/08Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on ..
BU
08/08Clovis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months En..
CI
08/08NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
07/20CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Resu..
BU
07/19Clovis Oncology Secures Long-Term Supply Agreement of Actinium-225 With NorthStar Medic..
MT
07/08Clovis Oncology Shares Drop Amid Heavy Volume After Shareholders Reject Plan for a Reve..
MT
07/07CLOVIS ONCOLOGY, INC. Submission of Matters to a Vote of Security Holders (form 8-K/A)
AQ
07/06CLOVIS ONCOLOGY, INC. : Other Events (form 8-K)
AQ
06/24CLOVIS ONCOLOGY, INC.(NASDAQGS : CLVS) dropped from Russell 2500 Index
CI
06/24CLOVIS ONCOLOGY, INC.(NASDAQGS : CLVS) dropped from Russell 2500 Growth Index
CI
06/24CLOVIS ONCOLOGY, INC.(NASDAQGS : CLVS) dropped from Russell Small Cap Completeness Index
CI
More news
News in other languages on CLOVIS ONCOLOGY, INC.
08/08Clovis Oncology, Inc. annonce ses résultats pour le deuxième trimestre et le semestre c..
07/19Clovis Oncology conclut un accord de fourniture à long terme d'Actinium-225 avec NorthS..
07/08Les actions de Clovis Oncology chutent dans un volume important après le rejet par les ..
06/14Clovis Oncology met en avant les données de phase 1 des études cliniques en cours sur l..
05/04Clovis Oncology, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2..
More news
Analyst Recommendations on CLOVIS ONCOLOGY, INC.
More recommendations
Chart CLOVIS ONCOLOGY, INC.
Duration : Period :
Clovis Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLOVIS ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 1,27 $
Average target price 2,25 $
Spread / Average Target 77,2%
EPS Revisions
Managers and Directors
Patrick J. Mahaffy President, Chief Executive Officer & Director
Daniel W. Muehl Principal Accounting Officer & Senior VP-Finance
Ginger L. Graham Chairman
Lindsey Rolfe Senior Vice President-Clinical Development
Thomas Fuglsang Harding Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
CLOVIS ONCOLOGY, INC.-46.49%209
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.94%40 375